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ttp://dx.doi.org/10.1016/j.ajpath.2014.06.003Stroke is the leading cause of adult disability and the fourth most common cause of death in
the United States. Inﬂammation is thought to play an important role in stroke pathology, but
the factors that promote inﬂammation in this setting remain to be fully deﬁned. An under-
studied but important factor is the role of meningeal-located immune cells in modulating
brain pathology. Although different immune cells trafﬁc through meningeal vessels en route
to the brain, mature mast cells do not circulate but are resident in the meninges. With the use
of genetic and cell transfer approaches in mice, we identiﬁed evidence that meningeal mast
cells can importantly contribute to the key features of stroke pathology, including inﬁltration
of granulocytes and activatedmacrophages, brain swelling, and infarct size. We also obtained
evidence that twomast cell-derivedproducts, interleukin-6 and, to a lesser extent, chemokine
(C-C motif) ligand 7, can contribute to stroke pathology. These ﬁndings indicate a novel role
for mast cells in the meninges, the membranes that envelop the brain, as potential gate-
keepers for modulating brain inﬂammation and pathology after stroke. (Am J Pathol 2014,
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Disclosures: None declared.Stroke, the leading cause of adult disability and the fourth
most common cause of death in the Unites States,1,2 occurs
when there is insufﬁcient blood ﬂow to the brain, and the
resultant injury initiates a cascade of inﬂammatory events,
including immune cell inﬁltration into the brain.3e5 This
post-stroke inﬂammation is a critical determinant of damage
and recovery after stroke; understanding the interplay be-
tween the immune system and the brain after stroke holds
much promise for therapeutic intervention.4e7 However,
successfully exploiting this therapeutic potential requires a
detailed understanding of the interplay between the immune
system and the brain after stroke.4
An understudied but important aspect of this interplay is
the role of meningeal-located immune cells in modulating
brain pathology. The meninges have long been recognizedgy.as an anatomical barrier that protects the central nervous
system (CNS). However, accumulating evidence suggests
that the meninges are important for communication between
the CNS and immune system during health and disease.8e10
All blood vessels pass through the meningeal subarachnoid
space before entering the brain, and this vascular connection
and the close proximity of the meninges to the underlying
Arac et alparenchymal nervous tissue make them ideally located to
act as a gatekeeper to modulate immune cell trafﬁcking to
the CNS. To support this gatekeeper function is evidence
that the meninges modulate brain inﬁltration of T cells,
neutrophils, and monocytes during meningitis and autoim-
mune conditions,11e14 with immune cells observed in some
instances accumulating in the meninges before they inﬁltrate
into the parenchyma.11,13
Emerging evidence suggests that the actions of immune cells
resident in the meninges are important for this gatekeeper
function.11,12,15 Mast cells (MCs), best known as proin-
ﬂammatory effector cells, can play critical roles in the devel-
opment of inﬂammation in many disease settings.16e18 MCs
reside in high numberswithin themeninges, but their function in
this site has not been fully investigated in stroke pathology.
Unlike most immune cells, mature MCs do not circulate in the
blood but are long-term residents of tissues, often in perivascular
locations, and can rapidly perform their functions in situ. CNS
MCs are found in the brain parenchyma and the meninges of
rodents and humans.18 It has been proposed that brain paren-
chymal MCs can enhance brain neutrophil numbers after stroke
and can exacerbate stroke pathology.19e24 However, much of
the evidence to support such conclusions is indirect. For
example, some of the studies that implicate MCs in stroke pa-
thology used pharmacologic approaches to interfere with MC
activation,19,20,22 but such drugs can have effects on other cell
types.25Moreover, the role of themeningealMCs inmodulating
post-stroke inﬂammation and pathology is unknown. Finally,
little is understood about which among the many MC-derived
mediators may be important in stroke pathology.17,26
To address these questions, we used genetic and cell
transfer approaches to study the role of MCs in the pathology
of ischemic stroke in mice. Speciﬁcally, we tested a c-kite
mutant mouse model (ie, WBB6F1-Kit
W/W-v mice) which is
profoundly MC deﬁcient and can be repaired of this deﬁ-
ciency by engraftment of in vitro-derived MCs from wild-
type (WT) mice. This MC knock-in approach enables the
MC-dependent effects in the mutant mice to be separated
from effects due to other abnormalities associated with their
mutation,11,17,26,27 because only the MC deﬁciency is
repaired by MC engraftment. Furthermore, one can investi-
gate the mechanisms by which MCs inﬂuence stroke pa-
thology by engrafting MCs from transgenic mice that lack
speciﬁc MC-associated products. We also tested our newly
described Cpa3-Cre; Mcl-1ﬂ/ﬂ mice, in which MC (and
basophil) numbers are reduced constitutively via Cre-
mediated depletion of the anti-apoptotic factor, myeloid
cell leukemia sequence 1 (Mcl-1), in the affected lineages.28
Cpa3-Cre; Mcl-1ﬂ/ﬂ mice lack the other abnormalities asso-
ciated with the c-kit mutations in WBB6F1-Kit
W/W-v mice.28
With the use of these in vivo models, we identiﬁed
meningeal MCs as important contributors to key features of
stroke pathology, including increased numbers of brain
granulocytes and activated macrophages, brain swelling,
and infarct size. We also obtained evidence that two
potentially proinﬂammatory MC-derived products, IL-62494and, to a lesser extent, chemokine (C-C motif) ligand 7
(CCL7), can contribute to pathology in this setting.Materials and Methods
Mice
Male c-kitemutant genetically MC-deﬁcient (WB/Rej-KitW/J
 C57BL/6J-KitW-v/J)F1-KitW/Wv (WBB6F1-KitW/W-v) mice and
their congenic WT (WBB6F1-Kit
þ/þ) littermates were
purchased from The Jackson Laboratory (Bar Harbor, ME).
KitW/W-vmice have a profound deﬁciency in MCs29 and certain
other hematological abnormalities; however, only the MC
deﬁciency is repaired byMC engraftment.17,26,30 KitW/W-vmice
have lower levels of neutrophils than the corresponding WT
mice in the bone marrow (BM), blood, and spleen and have a
mild anemia.27 W is a null allele of Kit and Wv is a point mu-
tation in the cytoplasmic tail of the receptor.17,26 Cpa3-
Cre;Mcl-1ﬂ/ﬂ mice are severely deﬁcient in MCs and also
have a marked deﬁciency in basophils.28 In these mice, Cre
recombinase is expressed under the control of carboxypepti-
dase A3 (Cpa3) promoter. Mcl-1 is an intracellular
anti-apoptotic factor that is required for MC survival. C57BL/
6-Cpa3-Cre; Mcl-1þ/þ mice were used as WT controls for
Cpa3-Cre;Mcl-1ﬂ/ﬂ mice. IL6eknock-out (KO) mice
(B6.129S2-Il6tm1Kopf/J) were purchased from The Jackson
Laboratory. CCL7-KOmice31 on a C57BL/6 background were
initially developed and were a kind gift from Israel F. Charo
(University of California San Francisco, San Francisco, CA).
All of the animal procedures were approved by Stanford Uni-
versity Administrative Panel on Laboratory Animal Care.MCeKnock-In Mouse Model
The MC deﬁciency in WBB6F1-Kit
W/W-v mice was selec-
tively repaired by systemic (intravenously through retro-
orbital injection under isoﬂurane anesthesia) or by menin-
geal administration of mouse BM-derived cultured MCs
(BMCMCs) generated in vitro, as indicated. As described
before,32 the femoral and tibial BM cells from WBB6F1-
Kitþ/þ, C57BL/6-Kitþ/þ, C57BL/6-IL6-KO, and C57BL/6-
CCL7-KO mice were cultured in 20% medium conditioned
by the growth of the WEHI-3 mouse myelomonocytic cell
line (containing IL-3) for 4 to 5 weeks. Before engraftment,
>95% of cultured cells were identiﬁed as BMCMCs
by May-Grünwald-Giemsa stain. For systemic engraft-
ment, 107 BMCMCs in 100 mL of phosphate-buffered sa-
line were injected retro-orbitally into 9- to 11-week-old
WBB6F1-Kit
W/W-vmice (50 mL into each retro-orbital side).
For meningeal engraftment, 106 BMCMCs or vehicle alone
(as a control) were injected into 9- to 11-week-old
WBB6F1-Kit
W/W-v mice, as described.15 The mice were
used for the experiments 8 to 10 weeks after either type (ie,
i.v. or meningeal) of engraftment. In experiments that used
such MC-engrafted mice, WT mice and MC-deﬁcient miceajp.amjpathol.org - The American Journal of Pathology
Role of Meningeal Mast Cells in Strokeused in the same experiments were the same age and housed
with the same conditions of husbandry.
Induction of Experimental Stroke
The mice were subjected to a ﬁlament occlusion model of
cerebral ischemia as described.6 The mice were habituated in
the surgery room overnight, and all of the surgeries were
initiated early in the morning. Brieﬂy, mice were anesthetized
by 1.5% to 2% isoﬂurane in a mixture of 1 L/minute of air and
0.2 L/minute of oxygen. The left external and common ca-
rotid arteries were permanently ligated. A hole was made in
the common carotid artery, and a 7-0, silicon rubber-coated,
reusable monoﬁlament (70SPRe2045; Doccol Inc., Sharon,
MA) was inserted and advanced toward the internal carotid
artery 9 to 10 mm after the carotid bifurcation to occlude the
left middle cerebral artery. The core body temperature was
measured by a rectal probe and maintained at 37C
throughout the surgery. Thirty minutes after its insertion, the
ﬁlament was removed to permit reperfusion. The surgical
wound was closed, and the mice were returned to their cages
with free access to water and food. We measured cerebral
blood ﬂow by using a laser Doppler ﬂow meter. The probe
was placed onto the skull 2 mm posterior and 5 to 6 mm
lateral to the bregma on the left side. No differences were
found in the presurgical weights of mice in any experiment. A
noninvasive CODA Monitor system (Kent Scientiﬁc, Tor-
rington, CT) was used to measure blood pressures and pulse
rates. Arterial blood gas and lactate levels were measured by
iSTAT CG4þ cartridges and a handheld blood analyzer
(Abbott Laboratories, Abbott Park, IL).
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) was performed at Stanford
Small Animal Imaging Facility by using the GE Healthcare
(Waukesha, WI) Micro-Signa software environment version
12M5 with a Varian 7 Tesla magnet, Research Resonance In-
struments BFG-150 to 90 gradient insert. The mice were anes-
thetized with 2% isoﬂurane in 2 L/minute of medical grade
oxygen while the respiratory rates were monitored, and the
surface body temperature was also monitored and kept at 34C
throughout the imaging. An in-house 2-cm diameter surface coil
was placed on the mouse skull to obtain the images. The T2-
weighted (T2W) imaging protocol parameterswere as follows: a
two-dimensional fast spin echo sequence with echo time
(TE)Z 82.5 ms, repetition time (TR)Z 4000 ms, echo train
lengthZ 8, axial slice thicknessZ 0.6 mm with no spacing,
ﬁeld of view Z 3 cm, matrix Z 128  128, number of
excitations (NEX)Z 10. The dicomﬁleswere opened inOsiriX
version3.3.2 (OsiriXFoundation,Geneva, Switzerland), and the
regions of interest were manually delineated. The hyperintense
areasof the stroke regionand the total ipsilateral andcontralateral
hemisphere areas (excluding the ventricles)weremeasured in 11
consecutive slices, starting approximately 2.5 mm anterior and
extending toward 3.5 mm posterior to the bregma.The American Journal of Pathology - ajp.amjpathol.orgAssessment of Infarct Size and Brain Swelling
The brain swelling was calculated by the following formula
that used T2WMRI obtained at 3 days after stroke:
Brain swellingZ100 ðtotal ipsilateral area
 total contralateral areaÞ=total contralateral area: ð1Þ
The MRI infarct sizes were calculated by the following
formula that used T2W-MRI obtained at 3 days or 2 weeks
after stroke:
Infarct sizeZ100 ½total contralateral hemisphere area
 ipsilateral healthy area=
ðtotal contralateral hemisphere areaÞ:
ð2Þ
The histological infarct size at 2 weeks after stroke was
calculated by using the same formula that used measurements
from silver-stained sections. For silver staining, the mice were
perfused transcardially with 30 mL of cold 0.9% NaCl, fol-
lowed by 30 mL of 3% balanced (pH 7.4) formalin solution.
The heads were kept overnight in 3% balanced formalin so-
lution, and then the brainswere transferred into a 20%sucrose/
3% formalin solution until they sank. Then, 30-mm sections
were cut with a cryostat. One in every 16 sections (11 sections
per brain) were stained with silver stain33 and scanned at 1200
dpi. The total ipsilateral, contralateral, and infarct areas were
measured with ImageJ version 1.44o (NIH, Bethesda, MD).
Isolation of Immune Cells from Brain and Blood
After induction of deep anesthesia, blood was collected through
cardiac puncture in EDTA syringes (50 mL of 2 mmol/L EDTA
for 1 mL of blood). The mice were perfused with 30 mL of cold
saline, the brains were removed immediately, the hemispheres
were split, and ipsilateral hemispheres were collected in
phosphate-buffered saline (Gibco, Carlsbad, CA) on ice. The
ipsilateral hemispheres were passed through a 70-mL cell
strainer in Hanks’ balanced salt solution (Gibco). Then, the
homogenates were incubated in 1 mL of 2 U/mL of Liberase CI
(Roche, Indianapolis, IN) in Hanks’ balanced salt solution for 1
hour at 37C, then centrifuged (490 g for 20 minutes without
brake)>30% Percoll. The cells were collected as the pellet and
washed with 10% fetal bovine serum (Gibco) in Dulbecco’s
modiﬁed Eagle medium (Gibco). The red blood cells in blood
were lyzed by lysis buffer (7.47 g of ammonium chloride and
2.04 g of Tris base in 1 L of ddH2O, pH 7.6), and the cells were
washed with 10% fetal bovine serum in Dulbecco’s modiﬁed
Eagle medium and kept on ice until staining.
Flow Cytometric Analysis
Cells were ﬁrst stained with 0.1% Live/Dead-Aqua (Invi-
trogen, Carlsbad, CA) to exclude the dead cells from the
analysis and then blocked with 1% anti-mouse CD16/32 (93)
(eBioscience, SanDiego, CA) antibody and 10%mouse serum2495
Arac et al(Jackson ImmunoResearchLaboratories Inc.,WestGrove,PA)
in a stainingbuffer [5%bovine serumalbumin (Sigma-Aldrich,
St. Louis, MO) and 2 mmol/L EDTA (Sigma-Aldrich) in
phosphate-buffered saline]. The cells were incubated with the
following antibodies for 20 minutes at 4C: anti-mouse CD45
(30-F11), CD11b (M1/70), Gr1 (RB6-8C5), F4/80 (BM8),
CD3e (17A2), CD8b (eBioH35 to 17.2), NK1.1 (PK136) (all
from eBioscience), and CD4 (RM4-5) (Invitrogen). The ﬂow
cytometric analysis was performed on a Becton Dickinson
LSR-II (Stanford Shared FACS Facility), and the data were
analyzed with FlowJo version 9.7.5 (TreeStar Inc., Ashland,
OR). The gates were set based on the unstained cells, and the
compensation was achieved by single-color stained BD-
CompBeads (BD Biosciences, San Jose, CA).
Histology and Quantiﬁcation of MCs
After perfusing each mouse under deep isoﬂurane anesthesia
with 30 mL of cold 0.9% NaCl and 30 mL of cold 3% buff-
ered formalin, the heads were removed and incubated over-
night in 3% buffered formalin solution. Then, the cranial
bones then were removed carefully so that the dura remained
on the brain surface. The dura was removed from the brain
surface by using a ﬁne-tip forceps, placed onto a slide with a
drop of water, and then spread out under a dissection micro-
scope to make a whole-mount preparation. The brain sections
were obtained as described in the Assessment of Infarct Size
and Brain Swelling section. Toluidine blue-stained brainMCs
were quantiﬁed in one of every four sections taken throughout
the brain, starting approximately 1.8mm anterior of bregma to
approximately 2.5 mm posterior of bregma. This approxi-
mately spans the region from where the corpus callosum ﬁrst
appears in coronal sections to mid-late hippocampus. This
includes the area where the highest numbers of MCs reside in
the brain (the area between hippocampus and thalamus).
Thirty-two sections were counted for each brain.
Statistical Analysis
All values are expressed asmeans SEM. The normality of the
data was determined by Kolmogorov-Smirnov test for each
group. For comparisons of more than two groups, we used one-
way analysis of variance followed by post hoc Tukey test or
Student’s t-test if the data were parametric, or the Kruskal-
Wallis test with post hoc Dunn test or U-test if the data were
nonparametric. For comparison of two groups, we used a two-
tailed Student’s t-test with Welch correction if the data were
parametric and a two-tailed U-test if the data were nonpara-
metric. Prism version 4.0c (GraphPad Software Inc., SanDiego,
CA) was used.P< 0.05was considered statistically signiﬁcant.
Results
MCs Can Increase Infarct Size after Stroke
We ﬁrst subjected MC-deﬁcient WBB6F1-Kit
W/W-v mice and
the corresponding WT mice (ie, WBB6F1-Kit
þ/þ) to stroke2496and used T2W-MRI to measure brain swelling and infarct
size. Compared with the corresponding WT mice, the MC-
deﬁcient mice exhibited signiﬁcantly less brain swelling
and smaller infarcts at 3 days after stroke (Figure 1, A, D,
and E) and signiﬁcantly smaller infarct size at 2 weeks after
stroke, whether quantiﬁed by T2W-MRI (Figure 1, B and
E) or histology (Figure 1, C and F). To evaluate whether
this reduction in stroke pathology could be reversed by
selective repair of the MC deﬁciency, MC-deﬁcient mice
were engrafted intravenously with BMCMCs from WT (ie,
WBB6F1-Kit
þ/þ) mice. These MC-engrafted mice exhibi-
ted brain swelling and infarct sizes similar to those of the
WT mice (Figure 1). By contrast, measurements of cerebral
blood ﬂow (Supplemental Figure S1), blood pressure,
arterial blood gases, blood glucose, and blood lactate
(Supplemental Tables S1 and S2) before, during, or after
stroke surgery found no statistically signiﬁcant differences
among the WT, MC-deﬁcient, and MC-engrafted animals.
Together, our data indicate that MCs can exacerbate stroke
pathology in WBB6F1-Kit
W/W-v mice without having
marked effects on cerebral blood ﬂow, blood pressure, heart
rate, or various measures of metabolic function.MCs Can Inﬂuence Numbers of Brain Leukocytes after
Stroke
We used ﬂow cytometry of leukocytes recovered from
mouse brains to quantify the effects of MCs on pop-
ulations of brain leukocytes at baseline and at 3 days or 2
weeks after stroke (Figure 2, A and B, and Supplemental
Figure S2A). There were few or no differences in
numbers of microglia (CD11bþCD45low) or lymphoid
cells (CD11bnegativeCD45high) among MC-deﬁcient mice
and their corresponding WT and intravenously MC-
engrafted groups, either before or 3 days or 2 weeks
after stroke, and only one such difference (higher numbers
of microglia at 2 weeks after stroke in WBB6F1-Kit
W/W-v
mice) reached statistical signiﬁcance (Figure 2C). In
contrast, MC-deﬁcient mice exhibited fewer cells in
the granulocyte and macrophage population (CD11bhigh
CD45high cells) at 3 days after stroke than did their corre-
sponding WT or MC-engrafted groups (Figure 2, A and D).
Although those differences did not achieve statistical sig-
niﬁcance, we analyzed the granulocyte and macrophage
population further by using Gr1 and F4/80 markers to
identify three subpopulations: granulocytes (Gr1þF4/80),
activated macrophages (Gr1þF4/80þ), and macrophages
(Gr1F4/80þ) (Figure 2B and Supplemental Figure S2B).
We found fewer granulocytes and activated macrophages in
the brains of MC-deﬁcient WBB6F1-Kit
W/W-v mice at 3 days
after stroke than in the corresponding WT or MC-engrafted
groups (Figure 2, C and E). Together, our results suggest
that MCs may contribute to increases in numbers of brain
granulocytes and activated macrophages in this stroke
model.ajp.amjpathol.org - The American Journal of Pathology
Figure 1 MCs can contribute to infarct size and brain swelling after stroke. Representative T2W-MRI of brains of WT (WBB6F1-Kitþ/þ) mice, MC-deﬁcient
(WBB6F1-Kit
W/W-v) mice, and MC-engrafted (WBB6F1-Kit
þ/þ BMCMCs/WBB6F1-Kit
W/W-v) mice at 3 days (A) or 2 weeks (B) after stroke. C: Representative silver-
stained serial coronal sections of brains of WT, MC-deﬁcient, and MC-engrafted mice at 2 weeks after stroke. Quantiﬁcation from T2W-MRI scans of brain
swelling at 3 days (D) and infarct size at 3 days and 2 weeks (E) after stroke. F: Quantiﬁcation of infarct size from brain sections obtained 2 weeks after stroke.
Data are expressed as means  SEM (DeF). Data were pooled from eight (E) and three (F) experiments, each of which gave similar results. The number of mice
in each group is indicated in each bar. *P < 0.05, **P < 0.01, and ***P < 0.005.
Role of Meningeal Mast Cells in StrokeMC-Deﬁcient Cpa3-Cre; Mcl-1ﬂ/ﬂ Mice Have Reduced
Brain Pathology after Stroke
In addition to their MC deﬁcits, MC-deﬁcient mice that have
abnormalities of c-kit structure or expression also have
additional hematopoietic deﬁciencies. For example, c-kite
mutant mice have defects in certain hematopoietic and other
cell populations.17,27 This fact has engendered considerable
recent discussion and debate about the value of these mice
for ascertaining MC functions in vivo.30,34,35 For this reason,
Reber et al30 have recommended using at least two different
lines of mice with distinct mechanisms of MC depletion, in
addition to using selective MC engraftment of MC-deﬁcient
mice, to provide strong support for conclusions about MC
function in models of disease or protective host responses.
We therefore also investigated the involvement of MCs in
stroke pathology by using Cpa3-Cre; Mcl-1ﬂ/ﬂ mice, which
have a severe deﬁciency of MCs by a mechanism that is
independent of mutations at c-kit.28 These MC-deﬁcient
mice have markedly reduced MC numbers in all tissues
examined (including lungs, skin, liver, and the dura mater,
which is part of the meninges) except for the spleen, whereThe American Journal of Pathology - ajp.amjpathol.orgthe numbers of MCs in Cpa3-Cre; Mcl-1ﬂ/ﬂ mice are similar
to that of the corresponding WT controls.28 Furthermore,
they lack other noneMC-related abnormalities found in the
c-kitemutant MC-deﬁcient mice; for example, although
Cpa3-Cre; Mcl-1ﬂ/ﬂ mice have reduced numbers of blood
basophils, these mice have normal numbers of blood neu-
trophils.28 At 3 days after stroke, Cpa3-Cre; Mcl-1ﬂ/ﬂ mice
had signiﬁcantly less brain swelling, smaller infarcts, and
fewer brain microglia, lymphoid cells, granulocytes, and
macrophages than the corresponding control Cpa3-Cre;
Mcl-1þ/þ mice (Figure 3). These data are consistent with
those obtained in experiments performed with the c-kite
mutant WBB6F1-Kit
W/W-v MC-deﬁcient mice and provide
further support for an important role for MCs in exacer-
bating brain pathology after ischemic stroke.
Importance of Meningeal MCs in Stroke-Induced
Pathology
We next sought to identify the speciﬁc MC populations in
the CNS which might contribute to pathology in stroke.
MCs reside in both the brain parenchyma and the meninges2497
Figure 3 MC-deﬁcient Cpa3-Cre; Mcl-1ﬂ/ﬂ mice have reduced pathology
after stroke. Quantiﬁcation at 3 days after stroke of brain swelling (A) and
infarct size (B) and numbers of microglia and lymphoid cells (C); granulocytes
and macrophages (D); granulocytes, Act. macrophages, and macrophages (E)
in Cpa3-Cre; Mcl-1þ/þmice (which have normal numbers of MCs and basophils)
and Cpa3Cre; Mcl-1ﬂ/ﬂmice (which have markedly reduced numbers of MCs and
also reduced numbers of basophils). Data are expressed as means SEM. The
number of mice in each group is indicated in each bar. *P< 0.05. PZ 0.07 for
lymphoid cells (C) and PZ 0.08 for granulocytes (E). Act., activated.
Figure 2 MCs contribute to inﬁltration of granulocytes and macro-
phages into the brain after stroke. Representative ﬂow cytometric plots of
CD11b-CD45 (A) and Gr1-F4/80 (B) brain immune cells at 3 days after
stroke in MC-deﬁcient (WBB6F1-Kit
W/W-v) mice and their corresponding WT
and MC-engrafted mice. Quantiﬁcation of the indicated immune cell pop-
ulations before (N) or 3 days or 2 weeks after stroke in MC-deﬁcient
WBB6F1-Kit
W/W-v mice and the corresponding WT mice and MC-engrafted
KitW/W-v mice (CeE). Data are expressed as means  SEM. n Z 9 to 10
animals per group for naive; n Z 8 to 12 animals for 3 days; n Z 8 to 9
animals for 2 weeks. *P < 0.05, **P < 0.01. Act., activated; N, naive.
Arac et alin WT mice.36e38 To compare the numbers and anatomical
distribution of MCs in the CNS of WT and MC-engrafted
mice, we quantiﬁed the MCs in the meninges (dura and
pia mater) and brain parenchyma of WT and MC-engrafted
mice before and after stroke. Both WT mice and MC-
engrafted mice had similar numbers of MCs in the dura
and pia mater both before and 2 weeks after stroke
(Figure 4, A and B). Interestingly, the density of MCs in
mouse dura mater (15 to 27 cells/mm2), calculated ac-
cording to our data, are similar to that reported for MCs in
the dura mater of humans (11 to 23 cells/mm2).39 In2498contrast to the meninges, the brain parenchyma of the MC-
engrafted mice had either no or substantially fewer MCs
than corresponding WT mice (Figure 4C). These data
strongly suggest that brain parenchymal MCs are not
responsible for the MC-dependent exacerbation of stroke
pathology we observed and instead suggest a potential role
for meningeal MCs in modulating the response to ischemic
injury.
To test this idea, we engrafted BMCMCs locally into the
meninges as described,11,15 rather than systemically by i.v.
transfer as was done in the previous experiments. After
meningeal engraftment of MCs, MC-engrafted WBB6F1-
KitW/W-v mice developed signiﬁcantly more brain swelling
and larger infarcts at 3 days after stroke than the MC-
deﬁcient mice and resembled the WT mice in both of
these features (Figure 5, AeC). Furthermore, both WT and
meningeal MC-engrafted WBB6F1-Kit
W/W-v mice had
similar numbers of microglia and lymphoid cells but
signiﬁcantly more brain granulocytes and activated
macrophages 3 days after stroke than the MC-deﬁcient
group (Figure 5, DeF). These results were similar to
those observed with systemic (i.v.) MC-engraftment in
WBB6F1-Kit
W/W-v mice (Figures 1 and 2) and are consis-
tent with the conclusion that meningeal MCs are sufﬁcient
to elicit the MC-dependent effects on lesion size and tissue
inﬁltration with granulocytes and macrophages observed
after stroke.ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Location of MCs in the CNS. Representative toluidine blue-stained images of and quantiﬁcation of MCs in dura mater (A), pia mater (B), and brain
parenchyma (C) of MC-deﬁcient WBB6F1-Kit
W/W-v mice and the corresponding WT mice and MC-engrafted KitW/W-v mice. MCs stain purple with toluidine blue;
arrows indicate representative MCs. Insets show magniﬁed images of MCs in each tissue. Data are expressed as means  SEM. The number of mice in each
group is indicated in (or over) each bar. *P < 0.05. Scale bars: 100 mm (AeC). N/A, not applicable.
Role of Meningeal Mast Cells in StrokeIdentiﬁcation of MC-Derived Factors that Inﬂuence
Stroke Pathology
MCs elicit their biological effects through secretion of a
variety of different factors, including cytokines and chemo-
kines.17 We selected two candidate MC-derived factors with
biological properties that have the potential to inﬂuence
stroke pathology (ie, IL-6 and CCL7) and tested them via the
MC engraftment approach. IL-6 has been reported to be an
important biomarker of disease severity in patients after
ischemic stroke, and cerebrospinal ﬂuid and plasma IL-6
levels correlate highly with infarct volume.40e42 However,
prior experimental studies in animals showed detrimental,
beneﬁcial, or even no effects of IL-6 on stroke patho-
logy,43e48 and it has been suggested that the post-stroke
effects of IL-6 may depend on its cellular source.47 CCL7
is a monocyte chemoattractant that is reported to be involved
in several disease entities and that is important for the release
of monocytes from the BM.31,49 Although the role of CCL7
in stroke pathology is not known, it has been reported that
CCL7 is induced after stroke in rats.50 To test whether IL-6
and/or CCL7 of MC origin might play a role in the
MC-dependent effects observed after stroke, we engrafted
BMCMCs from KO mice for each factor into the meninges
of the MC-deﬁcient WBB6F1-Kit
W/W-v mice. Control groups
included MC-deﬁcient mice engrafted in the meninges with
WT BMCMCs from either WBB6F1-Kit
þ/þ mice (the sameThe American Journal of Pathology - ajp.amjpathol.orgbackground as theWBB6F1-Kit
W/W-vmice) or C57BL/6 mice
(the same background as the ILe6- and CCL7-KO mice).
At 3 days after stroke, WBB6F1-Kit
W/W-v mice engrafted in
the meninges with WT BMCMCs of either WBB6F1 or
C57BL/6 origin exhibited features of stroke pathology that
were similar to each other and to those of theWT (ie,WBB6F1-
Kitþ/þ) mice (Figure 6), with signiﬁcantly greater brain
swelling, larger infarcts, and more brain granulocytes and
activatedmacrophages than in theMC-deﬁcient mice (Figure 6,
A, B, D, and E). These ﬁndings thus conﬁrmed our previous
results (Figure 5), indicating that meningeal MCs can exacer-
bate stroke outcome. In contrast, the pathology in ILe6-KO
MC-engrafted mice resembled that in the MC-deﬁcient mice,
with signiﬁcantly less brain swelling, smaller infarcts, and
fewer granulocytes and activated macrophages than in the WT
MC-engrafted mice (Figure 6, A, B, D, and E). CCL7-KOMC-
engrafted mice had trends for less brain swelling and fewer
granulocytes than the WT MC-engrafted mice, but these dif-
ferences did not reach statistical signiﬁcance (Figure 6, A, B, D,
and E). Numbers of MCs in the dura were similar among the
WT mice and the various meningeal MC-engrafted KitW/W-v
groups, suggesting that the differing extent of pathology among
the groups was not simply because of differing levels of
meningeal MC engraftment (Supplemental Figure S3).
Although we found MCs in the spleens of meningeal
MC-engrafted KitW/W-v mice (indicating that some of the
MCs reached sites outside of the CNS), the numbers were2499
Figure 5 Meningeal MCs are sufﬁcient to enhance pathology after stroke. Representative T2W-MRI images (A); quantiﬁcation of brain swelling (B) and
infarct size (C); and numbers of microglia and lymphoid cells (D); granulocytes and macrophages (E); granulocytes, Act. macrophages, and macrophages (F) in
brain 3 days after stroke in MC-deﬁcient WBB6F1-Kit
W/W-v mice and the corresponding WT mice and meningeal MC-engrafted KitW/W-v mice. Data are expressed as
means  SEM. The number of mice per group is indicated in each bar. *P < 0.05, **P < 0.01, and ***P < 0.005. P Z 0.07 for MC-deﬁcient versus MC-
engrafted groups for granulocytes (F). Act., activated.
Arac et alsubstantially lower than those of systemically (i.v.) engrafted
mice (data not shown). Together these data suggested that MC-
secreted IL-6 plays a major role in MC-dependent exacerbation
of injury after stroke, whereas the role of MC-secreted CCL7
was less prominent.
Discussion
This study provides evidence to indicate that meningeal
MCs can make important contributions to key features of
stroke pathology, including increasing numbers of brain
granulocytes and activated macrophages and exacerbating
infarct size and brain swelling. Furthermore, our data indi-
cate that MC-derived IL-6, and perhaps CCL7, can
contribute to the mechanisms by which MCs exacerbate
stroke pathology. These data imply a role for the meninges
in modulating brain pathology in stroke, and we have begun
to delineate the molecular pathways involved.2500We used different types of MC-deﬁcient mice to study the
role of MCs after stroke, which is important because con-
clusions about the effects of MCs in certain disease models
can vary according to the type of MC-deﬁcient mice ana-
lyzed.30,34,35,51e56 We compared results obtained in well-
established c-kitemutant MC-deﬁcient mouse models and
in a new, c-kiteindependent, cre-mediated MC-deﬁcient
mouse. As shown in the Results section, evidence derived
from the WBB6F1-KitW/W-v and Cpa3-Cre; Mcl-1ﬂ/ﬂ mouse
models of MC deﬁciency indicates that MCs can exacerbate
stroke pathology. When we performed experiments using
this model of stroke comparing C57BL/6 WT mice, MC-
deﬁcient C57BL/6-KitWsh/Wsh mice, and C57BL/6-
KitWsh/Wsh mice engrafted i.v. with WT BMCMCs, we
obtained results for infarct size at 3 days or 2 weeks, and for
granulocyte inﬁltration of the infarcted area at day 3 after
infarction, that were similar to those for the corresponding
experiments with WBB6F1 WT mice, MC-deﬁcient Kit
W/W-vajp.amjpathol.org - The American Journal of Pathology
Figure 6 MC-expressed IL-6 contributes to MC-
dependent exacerbation of stroke pathology.
Quantiﬁcation at 3 days after stroke of brain
swelling (A) and infarct size (B) from T2W-MRI
images and numbers of microglia and lymphoid
cells (C); granulocytes and macrophages (D);
granulocytes, Act. macrophages, and macrophages
(E) in the brain in the indicated groups of MC-
deﬁcient WBB6F1-Kit
W/W-v mice, WT (WBB6F1-
Kitþ/þ) mice, and MC-deﬁcient WBB6F1-Kit
W/W-v
mice engrafted in the meninges with WT BMCMCs
from WBB6F1-Kit
þ/þ (WT WBB6F1) or C57BL/6 (WT
B6) mice, or BMCMCs derived from B6 mice
genetically lacking (KO) IL-6 or CCL7 (MC-engraf-
ted mice). Data are expressed as means  SEM. The
number of mice per group is indicated in each bar.
*P < 0.05. PZ 0.1 for WT B6 MC-engrafted versus
B6 CCL7-KO MC-engrafted groups for granulocytes
(E). Act., activated.
Role of Meningeal Mast Cells in Strokemice or WT BMCMC-engrafted KitW/W-v mice [i.e., lower
values for the mast cell-deﬁcient mice than for the WT or
MC-engrafted Kit mutant mice (data not shown)]. However,
unlike the ﬁndings we obtained in the other two types of
MC-deﬁcient mice, most of the differences between the
results for the three different C57BL/6 mouse groups did not
reach the P < 0.05 level of statistical signiﬁcance, perhaps
because of phenotypic differences between C57BL/6 WT
and KitWsh/Wsh mice other than the MC deﬁciency of the
KitWsh/Wsh mice.30,34,35
Moreover, we provide strong evidence that meningeal
MCs were sufﬁcient to elicit the detrimental effects of MCs
after stroke. First, although CNS MCs are normally found
in both the meninges and brain parenchyma in WT mice,
they were only found in the meninges of the MC-engrafted
mice. This implies that brain MCs are not necessary for the
MC-dependent effects observed and that meningeal MCs
may be sufﬁcient to exacerbate stroke outcome. Second,
targeted repair of the meningeal MC deﬁciency stronglyThe American Journal of Pathology - ajp.amjpathol.orgsuggests that meningeal MCs are sufﬁcient to elicit the
effects seen.
To our knowledge, these data represent the ﬁrst evidence
that immune cells located in the meninges can modulate post-
stroke brain pathology and require a shift in current under-
standing of post-stroke inﬂammation. Given the perivascular
location of MCs and that blood ﬂow to the brain traverses the
meninges (Figure 7), meningeal MCs are ideally located to
modulate immune cell trafﬁcking to the brain during stroke.
Notably, evidence suggests that the meninges can play a role
in regulating immune cell trafﬁcking in other disease models
such as experimental autoimmune encephalomyelitis,11,14,15
supporting the general idea that the meninges can function
as a gatekeeper to modulate brain inﬂammation.57,58 More-
over, given the relative accessibility of the meninges (eg, via
intrathecal injectionda well-established route for drug de-
livery for treatment of malignancies that involve the
meninges59e61), targeting of meningeal MCs offers a po-
tential therapeutic strategy for overcoming the hurdle ofFigure 7 A: Scheme shows how the brain is
enveloped by the meninges that contain MCs in
both the dura mater and pia mater. B: Before
entering the brain parenchyma, blood vessels
course on the surface of the brain between the
dura mater and pia mater. Therefore, as a resident
immune cell in the meninges, the MC has the
potential to inﬂuence blood vessels and to func-
tion as a gatekeeper to inﬂuence brain inﬂam-
mation and pathology.
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approach that can potentially limit unwanted systemic
immunomodulatory side effects of such treatment. On the
basis of our identiﬁcation of meningeal MCs as key effectors
of stroke pathology in our mouse model, and in light of the
recent development of techniques to ameliorate inﬂammation
after brain injury via transcranial approaches,62 we think that
it will be of interest to determine whether there is evidence
that meningeal MCs can exacerbate stroke pathology in
humans and therefore might represent targets of novel
immunomodulatory strategies for limiting stroke pathology.
MCs function through the secretion of many mediators,
including various cytokines and chemokines.17 We found
that MCs which could not produce IL-6 failed to orchestrate
meningeal MC-dependent exacerbation of stroke pathology,
despite similar numbers and meningeal distribution of
IL-6edeﬁcient versus WT-engrafted MCs after their injec-
tion into the meninges of MC-deﬁcient mice. These results
indicate that MC-derived IL-6 is one MC-derived product
that has an important role in mediating the effects of MCs
on stroke pathology. This detrimental effect of MC-derived
IL-6 after stroke is of considerable interest, because prior
work has described detrimental, beneﬁcial, or even no ef-
fects of IL-6 on stroke pathology,43e48 and it has been
suggested that the post-stroke effects of IL-6 may depend on
its cellular source.47 We think that our data are the ﬁrst to
identify the role of IL-6 derived from a speciﬁc cell type in a
particular anatomical location in stroke pathology. By
contrast, we found that MC production of CCL7, a known
monocyte chemoattractant,31 had a less striking role after
stroke than did MC-derived IL-6. MC-derived IL-6 exac-
erbated key measured parameters of stroke pathology (ie,
brain swelling and infarct size, and numbers of brain gran-
ulocytes and activated macrophages), whereas MC-
produced CCL7 had its most notable effect (albeit not a
statistically signiﬁcant one) on brain granulocyte numbers,
with little effect on infarct size.
Given that cerebrospinal ﬂuid IL-6 levels correlate with
infarct size in patients after a stroke,42 our ﬁndings suggest
that enhanced production of MC-derived IL-6 in this setting
may contribute to the observed positive correlation between
cerebrospinal ﬂuid IL-6 levels and infarct size. However, an
important question that remains to be investigated is how
meningeal MCs are activated to secrete IL-6 and presum-
ably other mediators after stroke. The fact that the effects of
MCs on brain pathology were observed as early as 3 days
after stroke suggests that meningeal MCs may be activated
via innate signals,26 which could include products of com-
plement activation, ligands of Toll-like receptors, and/or
effects of damage-associated molecular patterns that may
originate from tissue damage in the brain parenchyma.
Another question that remains to be answered is how IL-6
(and other products of MC activation, because we have
directly studied only two of the many potential mediators
produced by MCs in this setting) ultimately exacerbate brain
pathology. One can speculate about several potential and not2502mutually exclusive mechanisms, including effects of secreted
factors that increase cell adhesion molecules on brain blood
vessel endothelial cells and/or local production of a spectrum
of chemoattractants, that together increase the migration of
granulocytes and other leukocytes to the area of damage;
effects of MC products on leukocyte function; direct toxic
effects of certain mediators on brain parenchymal cells
(neurons, glia, etc.); and effects of MC-derived products that
activate microglial cells to cause damage or orchestrate im-
mune responses that result in parenchymal injury.
Conclusion
We have identiﬁed evidence that meningeal MCs can
exacerbate stroke outcome in mice, highlighting a novel
function for the meninges after stroke as a gatekeeper to
modulate brain inﬂammation and pathology. By ﬁnding that
IL-6 production can represent one mechanism of action of
MCs in this setting, we have begun to delineate the MC-
dependent molecular pathways involved in modulating the
response to stroke. These ﬁndings also suggest that targeting
the meninges and/or MC-produced IL-6 might have thera-
peutic potential in stroke.
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